Joanne L. Blum, MD, PhD

Articles by Joanne L. Blum, MD, PhD

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

ByGabrielle Rocque,Joanne L. Blum, MD, PhD,Yan Ji,Eric Gauthier,Yao Wang,Monica Z. Montelongo,Joseph C. Cappelleri,Connie Chen,Meghan S. Karuturi,Debu Tripathy, MD

July 24th 2024

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

ByDebu Tripathy, MD,Joanne L. Blum, MD, PhD,Meghan S. Karuturi,Monica Z. Montelongo,Zhe Zhang,Eric Gauthier,Gabrielle Rocque

June 25th 2024

Update on the Management of Advanced Breast Cancer

ByJoanne L. Blum, MD, PhD

May 1st 1999

Fornier et al present an excellent summary of current treatment options and strategies for patients with metastatic breast cancer. This review summarizes currently available data (through the May 1998 American Society of Clinical Oncology

Latest Updated Articles

Update on the Management of Advanced Breast Cancer
May 1st 1999

Joanne L. Blum, MD, PhD

Articles by Joanne L. Blum, MD, PhD

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS

Update on the Management of Advanced Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology